2-Aryl/alkylamino-3-aryl I and 3-aryl/alkylamino-2-aryl pyridines II, as important potentially bioactive compounds, were synthesized by applying orthogonal cross-coupling strategies. Combinations of the Suzuki-Miyaura, LiebeskindSrogl, and Buchwald-Hartwig protocols gave access to the title compounds in a straightforward and operationally simple manner. Full control over the regioselectivity at the 2-and 3-positions was achieved by using 2,3-dichloropyridine or 3-iodo-2-(methylthio)pyridine as simple, commercially available starting materials. Within this contribution, efficient and high yielding conditions were developed for the Suzuki-

We present a concurrent chemo/biocatalytic one pot reaction cascade by combining a metal (Pd/Cu) assisted Liebeskind–Srogl coupling with an enantioselective enzymatic reduction for the production of chiral amines and alcohols.

No abstract

Intra-cardiac cell transplantation is a new therapy after myocardial infarction. Its success, however, is impeded by the limited capacity of donor cells to differentiate into functional cardiomyocytes in the heart. A strategy to overcome this problem is the induction of cardiomyogenic function in cells prior to transplantation. Among other approaches, recently, synthetic small molecules were identified, which promote differentiation of stem cells of various origins into cardiac-like cells or cardiomyocytes. The aim of this study was to develop and characterise new promising cardiomyogenic synthetic low-molecular weight compounds. Therefore, the structure of the known cardiomyogenic molecule cardiogenol C was selectively modified, and the effects of the resulting compounds were tested on various cell types. From this study, VUT-MK142 was identified as the most promising candidate with respect to cardiomyogenic activity. Treatment using this novel agent induced the strongest up-regulation of expression of the cardiac marker ANF in both P19 embryonic carcinoma cells and C2C12 skeletal myoblasts. The activity of VUT-MK142 on this marker superseded CgC; moreover, the novel compound significantly up-regulated the expression of other cardiac markers, and promoted the development of beating cardiomyocytes from cardiovascular progenitor cells. We conclude that VUT-MK142 is a potent new cardiomyogenic synthetic agent promoting the differentiation of precardiac mesoderm into cardiomyocytes, which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair. Additionally, an efficient synthesis of VUT-MK142 is reported taking advantage of continuous flow techniques superior to classical batch reactions both in yield and reaction time.

The complex dication of the diruthenium(II) compound {(mu-tppz)[Ru(bik)Cl]2}(ClO4)2 can be oxidized and reduced in two one-electron steps each. In CH3CN/0.1 M Bu4NPF6, the odd-electron intermediates{(mu-tppz)[Ru(bik)Cl]2}n+, n=1 and 3, have comproportionation constants of 7x10(8) and 1x10(5), respectively. Both exhibit near-infrared absorptions, in the case of n=3 the 1640 nm band (epsilon=1200 M-1 cm-1, Deltanu1/2=1560 cm-1) is attributed to an intervalence charge-transfer transition. While the mixed-valent intermediate (n=3) is EPR silent even at 4 K, the n=1 form shows g(parallel) 2.005 and g( perpendicular) 1.994 at that temperature, signifying a diruthenium(II) complex of the tppz*- radical anion. The variation of energy and intensity of nuCO and of the ring vibration band around 1590 cm-1 has been monitored not only for {(mu-tppz)[Ru(bik)Cl]2}n+, n=0-4, but also for the mononuclear {(tppz)Ru(bik)Cl}n+, n=0-2. In the dinuclear complex the carbonyl stretching bands of the spectator ligand bik are shifted by about 15 cm-1 on each one-electron-transfer step, increasing with the positive charge. The mixed-valent {(mu-tppz)[Ru(bik)Cl]2}3+ shows a perceptibly broader nuCO band, suggesting incomplete valence averaging (partial localization).